Characterization of a novel vasopressin V1b receptor antagonist, V1B-30N, in animal models of anxiety-like and depression-like behavior-Reference-Cited by-同舟云学术

Characterization of a novel vasopressin V1b receptor antagonist, V1B-30N, in animal models of anxiety-like and depression-like behavior

Published:2014-05 Issue: Volume:730 Page:157-163
ISSN:0014-2999
Container-title:European Journal of Pharmacology
language:en
Short-container-title:European Journal of Pharmacology

Author:

Hodgson Robert A.,Mullins Deborra,Lu Sherry X.,Guzzi Mario,Zhang Xiaoping,Bleickardt Carina J.,Scott Jack D.,Miller Michael W.,Stamford Andrew W.,Parker Eric M.,Varty Geoffrey B.

Publisher

Elsevier BV

Subject

Pharmacology

Reference33 articles.

1. Blockade of CRF(1) or V(1b) receptors reversed stress-induced suppression of neurogenesis in a mouse model of depression;Alonso;Mol. Psychiatry,2004

2. Effect of vasopressin V1b receptor antagonist, SSR149415, on anxiety-like behavior and Lewis lung carcinoma metastasis in mice;Amikishieva;Exp. Oncol.,2011

3. Vasopressin administration modulates anxiety-related behavior in rats;Appenrodt;Physiol. Behav.,1998

4. Central vasopressin administration failed to influence anxiety behavior after pinealectomy in rats;Appenrodt;Physiol. Behav.,2000

5. Characterization of the V1a antagonist, JNJ-17308616, in rodent models of anxiety-like behavior;Bleickardt;Psychopharmacology,2009

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Anxiety and the brain: Neuropeptides as emerging factors;Pharmacology Biochemistry and Behavior;2024-09

2. Precision Psychiatry Approach to Treat Depression and Anxiety Targeting the Stress Hormone System – V1b-antagonists as a Case in Point;Pharmacopsychiatry;2024-08-19

3. Arginine vasopressin in mood disorders: A potential biomarker of disease pathology and a target for pharmacologic intervention;Psychiatry and Clinical Neurosciences;2024-06-25

4. Neuroendocrine Regulation of Anxiety;Anxiety Disorders and Related Conditions;2024

5. Vasopressin receptor antagonists: a patent summary (2018-2022);Expert Opinion on Therapeutic Patents;2023-05-04